Dosing & Uses
Amyotrophic Lateral Sclerosis
Pending FDA approval for superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS)
Next:
Pharmacology
Mechanism of Action
Antisense medicine targeting superoxide dismutase 1 (SOD1), which is the second most common and best understood genetic cause of amyotrophic lateral sclerosis (ALS)
Tofersen binds to SOD1 mRNA, allowing for its degradation by RNase-H in an effort to reduce synthesis of SOD1 protein production
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
